- Matica Biotechnology has entered an agreement with University Health Network (UHN) to provide development and cGMP manufacturing services for an IL-10 adenoviral gene therapy program.
- The therapy is being developed for potential delivery to donor lungs during ex vivo lung perfusion (EVLP) prior to transplantation.
Matica Biotechnology, Inc. has announced an agreement with University Health Network (UHN) to support the development and manufacturing of an interleukin-10 (IL-10) adenoviral gene therapy intended for potential use in donor lungs during ex vivo lung perfusion (EVLP) before transplantation. Under the collaboration, the viral vector CDMO will provide development and cGMP manufacturing services for the program.
According to the companies, Matica Bio’s scope of work includes research cell bank generation, adenovirus seed synthesis and amplification, process development, analytical development, testing, master and working virus bank production, and cGMP manufacturing of the adenoviral vector. The activities are intended to support advancement of the therapy toward clinical development.
The gene therapy is designed for delivery during EVLP, a process that enables donor lungs to be assessed and treated outside the body before transplantation. Researchers are investigating whether combining EVLP with IL-10 gene therapy can reduce inflammation, improve graft function, and increase the availability and success of lung transplants.
“We are honored to work with UHN’s Toronto General Hospital to improve outcomes in lung transplantation. Our team brings deep expertise in adenoviral vector process development and cGMP manufacturing, and we look forward to supporting the advancement of this promising therapy toward clinical development.”
Paul Kim, CEO of Matica Bio
The agreement expands Matica Bio’s contract manufacturing activities in viral vectors and advanced therapies. The company said it continues to provide end-to-end CDMO services for programs spanning gene therapy, immuno-oncology, and regenerative medicine, from process development through cGMP production.
